Institutional Repository of Vilnius University
Naujų triazolo darinių priešvėžinio aktyvumo žmogaus plaučių, trejopai neigiamo krūties vėžio ir melanomos 2D ir 3D kultūrose įvertinimas /
Abstract
dc:descriptionBachelor’s thesis by D. Lukauskas / Supervisor: Prof. Dr. V. Petrikaitė; Laboratory of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas. Objective – to evaluate the anticancer activity of novel triazole derivatives in human lung, triple-negative breast cancer, and melanoma models in vitro. Tasks: 1. Evaluate the effect of triazole derivatives on the viability of human lung, triple-negative breast cancer, and melanoma cells. 2. Evaluate the effect of triazole derivatives on the migration of human lung, triple-negative breast cancer, and melanoma cells. 3. Evaluate the effect of triazole derivatives on the viability and growth of human lung, triple-negative breast cancer, and melanoma cells in three-dimensional cultures. Object – 14 triazole derivatives synthesized at Kaunas University of Technology. Methods. Viability of cancer cell lines (A549 – non-small cell lung cancer, MDA-MB-231 – triple-negative breast cancer, IGR39 – melanoma) was assessed using the MTT assay, and EC₅₀ values were calculated. Migration activity was evaluated using the wound healing assay by measuring the open wound area after 24–72 hours. In three-dimensional cultures, the effect on spheroid growth was evaluated based on diameter changes, and viability was assessed using the MTT assay. Spheroids were formed using magnetic 3D bioprinting. Molecular docking was performed by dr. M. Stasevych and dr. V. Zvarych (Lviv Polytechnic National University, Ukraine). Results. The MTT assay revealed effects on cancer cell viability, and six compounds were selected based on their activity: IT160, IT164, IT165, IT166, IT167, and IT168. EC₅₀ values were determined for these compounds using the Hill equation. Compound IT168 showed the highest activity across all tested cell lines, with EC₅₀ values of approximately 4 µM (A549 – 4.4 ± 0.9 µM, MDA-MB-231 – 4.3 ± 1.1 µM, IGR39 – 4.0 ± 0.8 µM). EC₅₀ values for the other compounds were 2–6 times higher. IT160 and IT167 were excluded from further analysis due to low selectivity. Migration assay results showed that the selected triazole derivatives did not inhibit A549, IGR39, or MDA-MB-231 cell migration at 10% and 50% of their respective EC₅₀ concentrations. Analysis of the effects of IT168 and dasatinib on spheroid growth and viability was hindered due to their influence on spheroid structure, thus rendering the analysis more difficult and less accurate compared to other compounds. The most active triazole derivatives did not inhibit the growth or viability of A549 spheroids at 10 µM concentration. In MDA-MB-231 spheroids, IT168 reduced spheroid diameter by ~7%, while IT164 and IT165 decreased viability to ~55–56%. In IGR39 spheroids, the most pronounced inhibition of growth was observed with IT168 (~30%), and the biggest reduction in viability was caused by IT164 and IT165 (~55%). Conclusions. None of the tested triazole derivatives inhibited the viability of A549, IGR39, or MDA-MB-231 cells more effectively than dasatinib. Compound IT168 showed the highest activity in all 2D cultures and was the only one to inhibit spheroid growth. IT164 and IT165 showed a greater effect on spheroid viability. The results suggest that compound IT168 is the most promising candidate for further investigation.
Degree
thesis:*- Grantor dc:publisher
- Institutional Repository of Vilnius University
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Lukauskas, Dainius,
Rights
dc:rights- Statement dc:rights
-
- info:eu-repo/semantics/openAccess
- Language dc:language
- lit
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.vu.lt/VU:ELABAETD239019455&prefLang=en_US